Verrica Pharmaceuticals/$VRCA
1D1W1MYTD1Y5YMAX
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
- Ticker
- $VRCA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 76
- Headquarters
- West Chester, United States
- Website
- www.verrica.com
VRCA Metrics
BasicAdvanced
$84M
-
-$1.88
1.49
-
Price and volume
Market cap
$84M
Beta
1.49
52-week high
$9.82
52-week low
$3.28
Average daily volume
54K
Financial strength
Current ratio
1.454
Quick ratio
0.993
Long term debt to equity
19.828
Total debt to equity
42.025
Interest coverage (TTM)
-7.08%
Profitability
EBITDA (TTM)
-25.964
Gross margin (TTM)
37.68%
Net profit margin (TTM)
-102.84%
Operating margin (TTM)
-87.18%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-43.98%
Return on equity (TTM)
473.29%
Valuation
Price to revenue (TTM)
2.66
Price to book
19.42
Price to tangible book (TTM)
19.42
Price to free cash flow (TTM)
-6.043
Free cash flow yield (TTM)
-16.55%
Free cash flow per share (TTM)
-0.806
Growth
Revenue change (TTM)
106.21%
Earnings per share change (TTM)
-70.58%
3-year revenue growth (CAGR)
52.16%
3-year earnings per share growth (CAGR)
-30.02%
VRCA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.